Sen. Hawley Urges FDA to Reinstate Abortion Drug Safety Regulations
The study found that more than 1 in 10 women who use mifepristone experience adverse side effects including sepsis, infection, hemorrhaging, or an emergency room visit.
Results from Tag: 'fda'
Trump’s Top Lawyer at FDA Resigns After Outcry Over Record Defending Abortion Pill
Here is a roundup of recent pro-life and abortion-related news.
‘Black Market’ Abortion Pills From Mexico Streaming Into US
The report by the American Life League criticizes government officials for doing little to stop a pro-abortion ‘cartel’ from shipping pills to states that ban or regulate access to abortion.
FDA and Abortion Pills: Supreme Court’s Decision Solely About ‘Standing’
COMMENTARY: An educated public remains the best defense against the FDA’s reckless actions.
On Abortion, Put Not Your Faith in Judges
EDITORIAL: Ultimately, our faith — when it comes to bringing an to end to legal abortion — shouldn’t rest in any branch of government.
After Supreme Court Abortion-Pill Ruling, US Bishops Call for Continued Prayer
The USCCB was part of an amicus brief with 10 other pro-life organizations, including Susan B. Anthony Pro-Life America, Catholic Health Care Leadership Alliance, and the Catholic Bar Association.
4 Questions the US Supreme Court’s Abortion Pills Decision Didn’t Decide
Abortion pills are a potential election issue this fall and beyond.
‘Women Should Be Outraged’: Lawmakers Urge Supreme Court to Restore Abortion-Pill Restrictions
Pro-life House members are urging the high court to restore what they believe are necessary restrictions on the abortion drug known as mifepristone.
Cancel-Culture Science: Medical Journal Withdraws Studies That Document Abortion-Pill Harm
EDITORIAL: For the abortion lobby as a whole, ‘conflict-of-interest’ considerations can arise in only one direction.
‘Groundbreaking’ Gene-Editing Therapy Receives Ethical Thumbs Up
Casgevy is a new treatment for sickle cell disease, a blood disorder that affects approximately 100,000 Americans.
